# Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

> **NCT01196676** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 63 (estimated)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** AZD4451
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01196676
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2011-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196676, "Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01196676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*